Avantor(US:AVTR) Globenewswire·2025-11-13 14:50Core Viewpoint - Avantor, Inc. is facing a class action lawsuit due to allegations of misleading investors about the company's competitive position and the impact of increased competition on its financial performance [1][3]. Summary by Sections Company Overview - Avantor, Inc. (NYSE: AVTR) provides scientific products and services across various sectors including biotechnology, pharmaceuticals, healthcare, education, and government [1]. Class Action Details - A class action was filed on behalf of investors who purchased Avantor common stock between March 5, 2024, and October 28, 2025, alleging that the company misrepresented its competitive positioning and the effects of competition [1]. Allegations - The complaint states that Avantor's management failed to disclose: 1. The company's competitive positioning was weaker than publicly represented 2. The negative effects of increased competition on the company's performance 3. The misleading nature of the company's statements regarding its business and prospects [3]. Financial Performance - On October 29, 2025, Avantor reported disappointing third-quarter results, including a -5% organic revenue growth, which was below prior guidance, and a net loss of $712 million attributed to a non-cash goodwill impairment charge of $785 million [4]. - The impairment charge was partly due to "competitive pressures" that significantly impacted the company's margins, and it was revealed that Avantor had lost several large accounts [4]. - Following this announcement, Avantor's stock price fell by $3.50 per share, a decline of over 23%, from $15.08 on October 28, 2025, to $11.58 on October 29, 2025 [4].